Encora Therapeutics Successfully Completes ULTRE Clinical Trial Evaluating Novel Wrist-Worn Wearable for Essential Tremor

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Encora Therapeutics is pleased to announce the successful completion of the ULTRE (Upper Limb Tremor Reduction in Essential Tremor) clinical trial. This study evaluated the safety, tolerability, and efficacy of Encora’s wrist-worn stimulation device for patients with essential tremor (ET), a tremor disorder affecting the upper limbs of an estimated 7.6 million Americans. Current treatment options for ET are often inadequate and poorly tolerated, underscoring the critical need for new therapeutic approaches.